Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Pulmonary Tuberculosis Age 18 to 75 years with body weight from 35 kg to 90 kg 2. Has not been treated for active TB within the past 3 years 3. Not yet on TB treatment 4. Xpert positive for M.tb 5. Rifampin-sensitive pulmonary tuberculosis as indicated by Xpert 6. Laboratory parameters within previous 14 days before enrollment: 1. Serum AST and ALT <3x upper limit of normal (ULN) 2. Creatinine <2x ULN 3. Hemoglobin >7.0 g/dL 4. Platelet count >50 x10(9) cells/L 7. Able and willing to return for follow-up visits 8. Able and willing to provide informed consent to participate in the study 9. Willing to undergo an HIV test 10. At sites with sufficient SARS-CoV-2 testing capacity and personal protective equipment for study staff, willing to undergo COVID-19 testing: viral RNA PCR testing for SARS-CoV-2 to determine active infection and antibody testing for SARS-CoV-2 to determine prior infection 11. Willing to have samples, including DNA, stored 12. Willing to consistently practice a highly reliable, non-hormonal method of pregnancy prevention (e.g., condoms) during treatment if participant is a premenopausal female unless she has had a hysterectomy or bilateral tubal ligation or her male partner has had a vasectomy. If hormonal contraception is used an additional method of pregnancy prevention (as above) should be used  Clinical suspicion of or confirmed extrapulmonary TB, including pleural TB 2. Pregnant or desiring/trying to become pregnant in the next 6 months or breastfeeding. 3. HIV infected 4. Currently COVID-19 infected 5. Unable to take oral medications 6. Diabetes as defined by point of care HbA1c greater than 6.5%, random glucose greater than 200 mg/dL (or 11.1 mmol/L), fasting plasma glucose greater than or equal to 126 mg/dL (or 7.0 mmol/L), or the presence of any antidiabetic agent (including traditional medicines) as a concomitant medicine 7. Disease complications or concomitant illnesses that may compromise safety or interpretation of trial endpoints, such as known diagnosis of chronic inflammatory condition (e.g. sarcoidosis, rheumatoid arthritis, connective tissue disorder) 8. Use of immunosuppressive medications, such as TNF-alpha inhibitors or systemic or inhaled corticosteroids, within the past 2 weeks 9. Use of any investigational drug in the previous 3 months 10. Substance or alcohol abuse that in the opinion of the investigator may interfere with the participant's adherence to study procedures. 11. Any person for whom the physician feels this study is not appropriate